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Introduction 
Delivery  of  pharmacological  agents  via  the  skin 
provides  distinct  benefits  compared  to  other 
conventional  routes  of  administration,  such  as 
minimizing adverse effects and toxicity due to a steady 
and  optimum  blood  levels,  bypassing  intestinal  and 
hepatic first pass effect, prevention of gastrointestinal 
irritation,  etc.
1-3  However,  transdermal  absorption  of 
most  drugs  often  results  in  a  low  bioavailability 
because  of  the  barrier  nature  of  the  skin.  The  most 
important reason of resistance to the passage of drugs 
through the skin is the stratum corneum, the outermost 
layer  of  the  skin.
1,2,4,5  In  order  to  enhance  the 
permeability  of  drugs  through  the  skin,  many 
techniques have been employed to overcome stratum 
corneum impermeability. A popular applied technique 
is  the  use  of  penetration  enhancers  which  reversibly 
decrease  the  barrier  resistance  of  the  skin.
3-5  These 
pharmacologically inactive  chemical  compounds  tend 
to  interact  with  the  stratum  corneum  constituents  to 
ease  the  absorption  of  drugs  through  the  skin  by 
temporarily increasing in skin permeability.
5  
Trolamine salicylate is a topically applied salicylic acid 
derivative which is used for temporary relief of pain or 
inflammation in muscles, joints and other tissues below 
the  skin.
6-10  As  trolamine  salicylate  is  an  odor  free 
compound and has no skin irritant properties
9, it can be 
a  viable  alternative  to  oral  salicylate  but  is  less 
permeable through skin compared with other salicylic 
acid derivatives like methyl salicylate.
11 Consequently, 
to achieve therapeutic concentrations of salicylic acid 
after transdermal administration of trolamine salicylate, 
the application of the penetration enhancers is needed.
12  
A number of penetration enhancers have been used to 
evaluate their influence on the in vitro permeation of 
trolamine  salicylate  through  the  abdominal  rat  skin. 
The  results  showed  that  the  best  enhancement  of 
trolamine salicylate flux, was obtained from 12 hours 
skin pretreatment with Transcutol
® (diethylene glycol 
monoethyl ether) and eucalyptus oil that were able to 
provide  a  near  12  and  10  fold  increase  in  flux, 
respectively, in comparison with controls.
12 However, 
effect of skin pre-treatment with these enhancers on in 
vivo  absorption  of  trolamine  salicylate  has  not  been 
investigated. Therefore, the aim of this study was  to 
assess the influence of pre-treatment with Transcutol
® 
and  eucalyptus  oil  on  percutaneous  absorption  of 
trolamine  salicylate  in  rat.  To  do  this,  both  non-
compartmental and non-linear  mixed  effect  modeling 
approaches were used to evaluate trolamine salicylate 
pharmacokinetics after its topical administration in rats 
with Transcutol
® and eucalyptus oil pre-treated skin. 
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Purpose: This study was conducted to assess the effect of skin pre-treatment with 
Transcutol
® and eucalyptus oil on systemic absorption of topical trolamine salicylate in 
rat. Methods: Pharmacokinetic parameters of salicylic acid following administration of 
trolamine salicylate on rat skin pre-treated with either Transcutol
® or eucalyptus oil 
were determined using both non-compartmental and non-linear mixed effect modeling 
approaches  and  compared  with  those  of  control  group.  Results:  Median  (%  of 
interquartile range/median) of salicylic acid AUC0-8hr (ng/mL/hr) values in Transcutol
® 
or
 eucalyptus  oil  treated  rats  were  2522(139%)  and  58976(141%),  respectively  as 
compared to the 3023(327%) of the control group. Skin pre-treatment with eucalyptus 
oil  could  significantly  decrease  extravascular  volume  of  distribution  (V/F)  and 
elimination  rate  constant  (k)  of  salicylic  acid.  Conclusion:  Unlike  Transcutol
®, 
eucalyptus oil lead to enhanced transdermal absorption of trolamine salicylate through 
rat skin. 
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Materials and Methods 
Chemicals 
Trolamine salicylate, potassium dihydrogen phosphate, 
perchloric acid and acetonitrile ( HPLC-grade ) were 
purchased  from  Merck,  Germany.  Eucalyptus  oil, 
containing 70% 1,8 – cineole was from Barij Essence 
Company,  Kashan,  Iran  .  Transcutol
®P 
(diethyleneglycol monoethyl ether) was kindly donated 
by Gattefosse, France. 
 
Animal Experiments and Drug Administration 
The study was approved by the ethics committee of the 
Vice  Chancellor  for  Research  and  Technology  of 
Ahvaz Jundishapur University of Medical Sciences. In 
vivo experiment was done on male wistar rats weighing 
235  ±  20  g  which  supplied  by  Animals  Care  and 
Breeding Center of Ahvaz Jundishapur University of 
Medical Sciences. Twelve hours before application of 
penetration  enhancers  (one  day  prior  to  dosing),  the 
hair of the abdominal region was removed with electric 
hair clippers. The rats were divided into three groups. 
In pre-treated groups Transcutol
® (N=10) or eucalyptus 
oil (N=5) in the form of closed dressing were applied to 
the  hairless  surface  of  abdominal  skin  for  12  hours. 
Subsequently, the closed dressing was removed and the 
pre-treated site was carefully wiped clean 50 times with 
cotton to remove the excess solution and then 1 gram of 
10%  trolamine  salicylate(PERRIGO
®,  USA)  was 
applied to the pre-treated skin. In control group (N=7), 
trolamine salicylate was applied to the not-treated skin. 
Application area of depilated abdominal skin was 12 
cm
2 (3 × 4 cm). Rats were under sleep condition with 
140  mg/kg  intra-peritoneal  phenobarbital  during  the 
period of pretreatment, application of drug and blood 
sampling.  Blood  samples  were  collected  from  a 
heparinized catheter inserted into the tail vein at 0.5, 1, 
2, 4, 6, 8 and 10 hours (when it was possible) after 
administration  of  drug.  Plasma  samples  were 
immediately separated by centrifugation at 13,000 rpm 
for 5 minutes and were stored at -70 °C until the time 
of analysis. 
 
Analytical Procedure 
Salicylic  acid  concentration  in  rat  plasma  following 
topical  administration  of  trolamine  salicylate  was 
determined  using  high-performance  liquid 
chromatography (HPLC) with fluorescence detection as 
previously  reported  with  some  modifications.
13  The 
HPLC apparatus consisted of an Agilent 1260 Infinity 
quaternary  pump  and  Agilent  1260  Infinity 
fluorescence  detector  (Agilent,  USA  )  .  An  Alltech 
Altima
® C18 column (150 mm × 2.1 mm, 5 µm particle 
size) (Grace Davison Discovery Sciences, USA) was 
used for the separation. The mobile phase consisted of 
acetonitrile: phosphate buffer (17: 83) (pH 3) delivered 
at  a  flow  rate  of  0.5  ml/min.  Fluorescence  detection 
was  performed  at  297  nm  (excitation)  and  407  nm 
(emission). Plasma samples (50  μL) were transferred 
into a 1.5-ml micro-centrifuge  tubes and mixed  with 
100 μL of perchloric acid 35%. After vortex mixing for 
1  min,  300  μL  of  acetonitrile  was  added  to  this 
solution. The contents were vortex mixed thoroughly 
for 2 minutes and centrifuged at 1500 g for 5 minutes. 
Twenty μL of the clear supernatant was injected onto 
the column. 
 
Pharmacokinetic Analysis 
Non-Compartmental Analysis 
Area under the salicylic acid plasma concentration time 
curve  between  0  and  8  hours  post  administration  of 
trolamine  salicylate  (AUC0-8  hr)  was  calculated  using 
trapezoidal rule to compare the extent of absorption in 
rats with Transcutol
® or eucalyptus oil pre-treated skin 
with  that  of  the  control  group.  Kruskal-Wallis  test 
followed  by  pairwise  multiple  comparisons  (SPSS 
Statistics  20,  IBM,  USA)  was  used  to  check  any 
significant difference of AUC values between treatment 
groups. 
Non-linear  mixed  effect  modeling:  Salicylic  acid 
plasma  concentration  –time  data  were  modeled  by  a 
one-compartment  model  with  zero-order  absorption 
input.  The  inter-animal  error  terms  for  all  structural 
model parameters including Tk0 (duration of zero order 
absorption), k (first order elimination constant) and V/F 
(extravascular  apparent  volume  of  distribution)  were 
assumed  to  be  independently  and  log-normally 
distributed with mean zero and variance ω
2. A constant 
error  model  was  used  for  the  residual  random 
variability. Covariate analysis was also done to assess 
the effect of skin pre-treatment on trolamine salicylate 
pharmacokinetics.  Influence  of  pre-treatment  on  the 
pharmacokinetic  parameters  were  modeled  using  the 
following general equation:
14 
                                                    
in  which  Pi,  pre-treated  and  Pi,  control  are  the  population 
values of pharmacokinetic parameter i in each of pre-
treated groups and control group, respectively. βi is the 
pre-treatment effect for parameter i. Non-linear mixed 
effect  analysis  was  carried  out  using  Monolix  4.2.0 
(Lixoft,  France).  Model  selection  was  based  on  the 
significant  reduction  in  minimum  objective 
function(MOF) that is equal to -2×log likelihood value; 
parameter  precision(expressed  as  relative  standard 
errors  of  the  estimated  parameters)  and  visual 
inspection  of  goodness-of-fit  plots  including  the 
prediction distribution graph.  Discrimination  between 
two  nested  models  (e.g.  with  and  without  covariate 
effect) was carried out using log-likelihood ratio test 
assuming a chi-squared distribution for the difference 
between  minimum  objective  function  values.  A 
significance level of 0.005 corresponding to a decrease 
of 7.879 (1 degree of freedom) in minimum objective 
function was considered. 
 
Results and Discussion 
Salicylic Acid Analysis Method 
The linear dynamic quantitation range of the employed 
HPLC  method  was  between  25(limit  of  quantitation)  
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and  5000  ng/mL  in  rat  plasma  with  a  correlation 
coefficient of 0.999. The intra- and inter-day accuracy 
for salicylic acid over the above concentration range 
fell  in  the  ranges  of  99-100  %  and  110-113%, 
respectively with the analytical recovery of greater than 
85%. The intra- and inter-day precision were 5-6% and 
3-13%, respectively. 
 
Non-Compartmental Analysis 
Plasma  concentration  time  profiles  of  salicylic  acid 
following topical administration of trolamine salicylate 
in  different  groups  of  rats  with  Transcutol
®-  or 
eucalyptus oil pre-treated skin in comparison to control 
group( without any skin pre-treatment) is presented in 
Figure 1. Median values of AUC0-8 hr (% of interquartile 
range/median)  were  2522(139%),  58976(141%), 
3023(327%) ng/mL/hr for Transcutol
®, eucalyptus oil 
and control groups, respectively. As could be seen from 
Figure  2,  significant  differences  were  observed 
between median value of AUC0-8 hr in rats which their 
skins were pre-treated with eucalyptus oil with those of 
Transcutol
® (p =0.030) and control ( p=0.004)groups. 
However,  no  statistically  significant  difference  was 
detected  between  the  median  of  AUC0-8  hr  in  control 
and Transcutol
® pre-treated rats. Furthermore, the inter-
animal variability in AUC0-8 hr was lower in rats with 
either Transcutol
® or eucalyptus oil pre-treated skin as 
compared to control group. 
 
Figure 1. Median plasma concentration-time profile of salicylic 
acid following topical administration of trolamine salicylate in 
different groups of rats with Transcutol- or eucalyptus oil pre-
treated skin in comparison to control group (dashed lines with 
the same color represent 95 % confidence around the median 
values). 
 
Non-Linear Mixed Effect Modeling  
Any attempt to estimate salicylic acid elimination rate 
constant  (k)  with  enough  precision  was  unsuccessful 
that  could  be  related  to  insufficient  plasma 
concentration-time data of the elimination phase in the 
majority of the rats under investigation. Therefore, the 
population value of k was fixed to 0.105 hr
-1 which has 
been reported by Varma et al in a group of male rats 
with the same range of age and weight.
15 Parameters of 
the  base  population  model  (model  without  including 
any  covariates)  are  presented  in  Table  1.  Bayesian 
individual  rats’  estimates  of  pharmacokinetic 
parameters were used for covariate screening. As could 
be  seen  from  Figure  3,  statistically  significant 
differences  were  observed  between  the  median  of 
individual estimates of the pharmacokinetic parameters 
in eucalyptus oil pre-treated rats with both Transcutol 
pre-treated and control groups. So, the influence of pre-
treatment  on  the  pharmacokinetic  parameters  of 
salicylic acid was further assessed by including it as a 
categorical covariate in the population model. Results 
of covariate analysis are shown in Table 2. Although, 
inclusion  of  both  pre-treatments(with  Transcutol  and 
eucalyptus  oil)  as  an  influential  covariate  on  all 
pharmacokinetic  parameters  led  to  statistically 
significant reductions in MOF values, the estimated β 
coefficients were not enough precise(p-values greater 
than 0.05). In case of model with pre-treatment effect 
on Tk0 alone (second model in Table 2), the estimated 
values of Tk0 did not make sense (4 hour for control 
group). 
 
Figure 2. Comparison of area under the salicylic acid plasma 
concentration-time  curve  up  to  8  hours  (AUC0-8hr)  post 
administration  of  100  mg  trolamine  salicylate  (1g  of  10% 
cream) in rats with untreated, Transcutol or eucalyptus oil pre-
treated skin. 
 
Table  1.  Pharmacokinetic  parameters  of  salicylic  acid  base 
population  model  (model  without  pre-treatment  effect  as  a 
categorical  covariate)  following  topical  administration  of 
trolamine  salicylate  in  rats  with Transcutol-  or  eucalyptus  oil 
pre-treated skin and control group.  
Parameter  Value 
a SE  Relative SE (%) 
Tk0(hr)  13.8  3.1  23 
V/F(mL)  13.2  4.5  35 
b k(hr
-1)  0.105  -  - 
c ωTk0  0.53  0.17  32 
c ωV  1.13  0.26  23 
c ωk  2.55  0.56  22 
Residual error(ng/mL)  413  24  6 
a Standard error of estimate 
b Not estimated 
c  Inter-individual variability of pharmacokinetic parameters 
in log-normal domain  
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Figure  3.  Comparison  of  base  model  (without  pre-treatment 
effect  as  a  covariate)  individual  estimates  of  salicylic  acid 
pharmacokinetic  parameters  after  topical  administration  of 
trolamine salicylate between different groups of rats with and 
without  skin  pre-treatment.  Box  and  horizontal  line  inside  it 
represents 25 - 75 percentile range and median, respectively. 
Non-outlier  minimum  and  maximum  observed  values  are 
shown by whiskers. 
 
As  could  be  seen  from  Table  2,  effect  of  skin  pre-
treatment  with  Transcutol  on  pharmacokinetic 
parameters  of  salicylic  acid  was  not  statistically 
significant.  Therefore,  in  the  next  step  of  covariate 
analysis,  Transcutol
®  and  control  group  rats  were 
pooled into one group as not-treated with eucalyptus 
oil. The final selected covariate model (shown in italic 
letters) was the one that assumes a significant effect of 
skin pre-treatment with eucalyptus oil on extravascular 
volume of distribution and elimination rate constant of 
salicylic acid. Considering a covariance between Tk0 
and V/F resulted in better estimates of all parameters. 
Prediction  distribution  of  salicylic  acid  plasma 
concentration by the final population model along with 
the observed data are shown in Figure 4. The majority 
of  the  observed  concentration  data  lie  within  the  90 
percent confidence interval of the model prediction. 
 
 
Table 2. Comparison of different models with skin pre-treatment as a covariate (levels of significant difference of the β parameters are 
given in parenthesis). 
Model 
-2log-likliehood 
(
a MOF) 
b ΔMOF 
c β1 
d β2 
e β3 
f β4 
g β5 
h β6 
Base model(no-covariate effect)  2870.56  -  -  -  -  -  -  - 
Effect of pre-treatment on Tk0  2833.61  -36.95 
2.19 
(0.0019) 
0.74 
(<0.0001) 
-  -  -  - 
Effect of pre-treatment on V/F  2844.93  -25.63  -  - 
0.12 
(0.75) 
-2.02 
(<0.0001) 
-  - 
Effect of pre-treatment on k  2853.97  -16.59  -  -  -  - 
-0.70 
(0.53) 
-1.73 
(0.0014) 
Effect of pre-treatment on Tk0 and V/F  2840.70  -29.86 
0.70 
(
 i -) 
0.07 
(0.87) 
-0.22 
(0.69) 
-1.98 
(<0.0001) 
-  - 
Effect of pre-treatment on Tk0 and k  2846.82  -23.74 
1.39 
(0.0520) 
1.13 
(0.11) 
-  - 
-2.86 
(0.77) 
-1.53 
(0.0001) 
Effect of pre-treatment on V/F and k  2834.02  -36.54  -  - 
0.36 
(0.21) 
-1.83 
(<0.0001) 
-1.99 
(0.65) 
-1.16 
(<0.0001) 
Effect of pre-treatment on Tk0 , V/F and k  2831.93  -38.63 
1.32 
(1) 
-0.24 
(0.71) 
-0.52 
(0.63) 
-1.79 
(<0.0001) 
-.53 
(0.63) 
-1.26 
(<0.0001) 
j Effect of eucalyptus oil on Tk0  2860.15  -10.41  - 
-1.48 
(0.021) 
-  -  -  - 
j Effect of eucalyptus oil on V/F  2844.56  -26.00  -  -  - 
-2.01 
(<0.0001) 
-  - 
j Effect of eucalyptus oil on k  2853.51  -17.05  -  -  -  -  - 
-1.89 
(0.0005) 
j Effect of eucalyptus oil on V/F and k  2834.62  -35.94  -  -  - 
-1.98 
(<0.0001) 
- 
-1.96 
(0.012) 
j Effect of eucalyptus oil on Tk0 and V/F  2841.62  -28.94  - 
-0.11 
(0.84) 
- 
-2.03 
(<0.0001) 
-  - 
j Effect of eucalyptus oil on Tk0 and k  2849.24  -21.32  - 
-1.73 
(0.007) 
-  -  - 
-1.48 
(<0.0001) 
j Effect of eucalyptus oil on Tk0, V/F and k  2832.75  -37.81  - 
-0.46 
(0.42) 
- 
-1.85 
(<0.0001) 
- 
-1.31 
(0.0001) 
j, k Effect of eucalyptus oil on V/F and k 
assuming a covariance between Tk0 and V/F 
2833.48  -37.08  -  -  - 
-2.20 
(<0.0001) 
- 
-1.63 
(0.0015) 
a Minimum objective function; 
b in comparison to the base model; 
c coefficient of the effect of Transcutol  pre-treatment on Tk0; 
d 
coefficient of the effect of eucalyptus oil pre-treatment on Tk0; 
e coefficient of the effect of Transcutol pre-treatment on V/F; 
f coefficient 
of the effect of eucalyptus oil pre-treatment on V/F; 
g coefficient of the effect of Transcutol pre-treatment on k; 
h coefficient of the effect 
of eucalyptus oil pre-treatment on k; 
i could not be calculated; assuming no difference between phar macokinetic parameters of rats in 
Transcutol and control groups and putting them into one group as not0treated with eucalyptus oil; 
k final selected model 
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Figure  4.  Prediction  distribution  of  salicylic  acid  plasma 
concentration following administration of trolamine salicylate to 
rats by the final population model including skin pre-treatment 
with  eucalyptus  oil  as  an  influential  covariate  (color  bands 
represent different prediction percentiles) 
 
Parameters of the final selected model are presented in 
Table  3.  Results  indicated  that  inclusion  of  pre-
treatment with eucalyptus oil could lead to substantial 
reduction in inter-animal variability of pharmacokinetic 
parameters.  
 
Table  3.  Pharmacokinetic  parameters  of  salicylic  acid  final 
population  model  (model  including  pre-treatment  with 
eucalyptus  oil  as  a  categorical  covariate)  following  topical 
administration of trolamine salicylate in rats with Transcutol- or 
eucalyptus oil pre-treated skin and control group. 
Parameter  Value 
a SE 
Relative 
SE (%) 
Tk0(hr)  17.3  3.0  17 
V/F(mL)  24.0  4.1  17 
b βeucalyptus oil effect on V/F  -2.2  0.25  11 
c k(hr
-1)  0.105  -  - 
d βeucalyptus oil effect on k
  -1.63  0.51  31 
e ωTk0  0.64  0.13  21 
e ω V/F  0.41  0.11  26 
e ω k  0.70  0.34  49 
correlation between Tk0 
and V/F 
0.81  0.17  21 
V/F eucalyptus oil group(mL)  2.7  0.5  18 
V/F other groups(mL)  24.0  4.1  17 
k eucalyptus oil group(hr
-1)  0.021  0.01  51 
k other groups(hr
-1)  0.105  -  - 
Residual error(ng/mL)  416  24  6 
a Standard error of estimate 
b Significant at p <0.0001 
c Not estimated 
d Significant at p = 0.0015 
e Inter-animal variability of pharmacokinetic parameters in 
log-normal domain 
 
Lower extravascular apparent volume of distribution in 
rats with eucalyptus oil pre-treated skin as compared to 
other  groups,  might  be  due  to  the  enhanced 
bioavailability (increase in F) of trolamine salicylate. 
On  the  other  hand,  a  considerable  decrease  in 
elimination  rate  constant  of  the  eucalyptus  oil  group 
rats, could be attributed to the saturation of salicylic 
acid  elimination  pathways  due  to  the  high  plasma 
concentration  of  salicylic  acid  achieved  following 
application of eucalyptus oil as transdermal penetration 
enhancer.
16,17  
Tk0 is not affected by pre-treatment, therefore the zero 
order  absorption  rate  is  not  different  among  three 
groups of rats. 
 
Permeation  Enhancing  Effect  of  Transcutol
®  and 
Eucalyptus Oil 
The results of the present study show that eucalyptus 
oil  created  an  appreciable  increase  in  transdermal 
absorption  of  trolamine  salicylate  through  rat  skin 
compared with the control while Transcutol
® did not 
have  any  significant  enhancing  effect  on  trolamine 
salicylate permeation. 
The  inability  of  Transcutol
®  to  promote  transdermal 
permeation of trolamine salicylate in the present study 
is  inconsistent  with  the  finding  of  in  vitro  study  of 
Sharif Makhmalzade and Hasani.
12 In their experiments 
Transcutol
® was found to cause the best enhancement 
of  trolamine  salicylate  flux  (12  fold)  followed  by 
eucalyptus oil (10 fold) in comparison to control. Such 
a  lack  of  correlation  between  in  vitro  and  in  vivo 
permeability  of  triethanolamine  salicylate  was  also 
reported by Cross et al during their study on topical 
penetration of salicylate esters and salts using human 
isolated skin and clinical microdialysis technique. They 
suggested  that  there  is  a  possibility  that  in  vivo 
salicylate  in  the  epidermis  could  not  be  released  as 
quickly  as  in  vitro  because  of  differences  in  sink 
condition  or  some  sorts  of  strong  binding  to  tissue 
constituents.
18 
According to the contradictory results that have been 
published in the literature, Transcutol
® can increase or 
decrease  transdermal  delivery  of  topically  applied 
compounds.  It has  been reported  that prostaglandin
19 
and  theophylline
20  in  vitro  skin  permeability  was 
increased  by  the  presence  of  Transcutol
®  due  to  its 
solubilizing effect that increases the solubility of drug 
in  the  skin,  thus  provides  a  raising  in  drug 
partitioning.
21  However,  other  researchers  found  that 
Transcutol
®  was  not  able  to  show  any  significant 
enhancing  effect  on  the  percutaneous  absorption  of 
morphine,
22 salicylic acid
23 and melatonin.
24  
It  has  been  suggested  that  Transcutol
®  can  lead  to 
formation of cutaneous depot of drugs due to its ability 
to cause intercellular lipids swelling, thereby associated 
with drug entrapment in the skin.
25-27 In addition, high 
molecular weight of some drugs have been suggested to 
be  one  of  the  restrictions  for  Transcutol
® 
effectiveness.
28 
1,  8  Cineol  (eucalyptol)  is  the  principal  chemical 
component of eucalyptus oil. Cineol is a cyclic ether 
and tend to be more effective on hydrophilic drug (like 
salicylates)  permeation.  This  penetration  enhancer  
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affects  the  lipid  bilayer  structure  by  forming  liquid 
pools  in  those  region.  Thus  cineol  increases  skin 
permeability  by  disrupting  the  lipid  structure  of  the 
stratum corneum.
5,29,30 
 
Conclusion 
Unlike  eucalyptus  oil,  skin  pre-treatment  with 
Transcutol
®  could  not  lead  to  enhancement  of 
trolamine  salicylate  transdermal  absorption  in  rat. 
Eucalyptus  oil  could  result  in  more  than  20  fold 
increase in systemic absorption of trolamine salicylate 
through rat skin as compared to control group. 
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